Andy

GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older. Novavax’s vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on June 27, 2024.

RICHMOND, Va., Aug. 28, 2024 /PRNewswire/ — Activation Capital, an innovation ecosystem development organization, has announced the selection of 10 fast-growing startups from across the country for the inaugural Frontier BioHealth program, which commenced with an in-person gathering on August 8-9, 2024. Each company will benefit from highly specialized training, targeted mentorship, and extensive relationship-building opportunities to accelerate its growth in the life sciences and healthtech sectors.

Frontier BioHealth by Activation Capital is an educational and support program designed to provide highly specialized training, targeted mentorship, and relationship building to help scale pharmaceutical, biotech, medical device, and health-focused consumer products companies. As an independent nonprofit corporation operating on behalf of the Virginia Research Biotechnology Partnership Authority, Activation Capital is committed to advancing life sciences and other cutting-edge technologies through scientific research, commercialization, and ecosystem development.

ARLINGTON, Va., Aug. 28, 2024 /PRNewswire/ — OxiWear, a pioneering company in wearable health technology, is proud to announce that it has received clearance from the U.S. Food and Drug Administration (FDA) for its cutting-edge oxygen monitoring device. This certification marks a significant milestone in OxiWear’s mission to revolutionize patient care and enhance the quality of life for individuals with chronic diseases.

OxiWear is a cutting-edge ear pulse oximeter designed for continuous, real-time measurement of blood oxygen saturation (SpO₂) and pulse rate. This device provides unmatched accuracy and convenience while still and during motion, across all skin types, within clinical and home environments. Unlike traditional methods, OxiWear ensures that patients and healthcare providers have constant access to important oxygen saturation data. The continuous data collection capability is vital for the early detection of hypoxemia (low oxygen levels), offering prompt haptic and emergency messaging alerts that can potentially save lives.

Rural Maryland-based biotechnology business seeks to develop new methods for image-based tissue diagnostics and assays

COLUMBIA, Md., (August 27, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $25,000 Pre-Seed Rural Business Innovation Initiative (RBII) investment in NEOPATHOLOGY CORP. TEDCO’s RBII was designed to enhance technology commercialization and provide technical and business assistance to small and early-stage companies based in rural Maryland.

“Our proprietary approach standardizes the tissue diagnostic process using contemporary spatial biology-enabling platforms,” said Paul Aiyetan, founder, CEO and director of NEOPATHOLOGY CORP. “Through this process, we are hoping to reduce diagnostic errors, improve diagnostic accuracy and expedite the time to treatment initiation. Thanks to TEDCO’s investment, we can continue progressing towards our goals.”

Johns Hopkins Technology Ventures (JHTV) has proudly released its FY24 Annual Report, marking ten years of exceptional growth in innovation and entrepreneurship. The report highlights JHTV’s significant achievements, including a fourfold increase in venture investments and a tripling of annual licensing revenue. These accomplishments underscore JHTV’s critical role in translating groundbreaking research into impactful technologies.

The report also celebrates the establishment of the Pava Marie LaPere Center for Entrepreneurship, which continues to nurture student and community innovation at Johns Hopkins. In addition to these milestones, JHTV has spearheaded collaborations, secured substantial funding, and supported the growth of new startups, further solidifying its position as a leader in academic technology transfer.

COLUMBIA, Md., (August 26, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Pre-Seed Builder Fund investment in Simmbion, LLC. Businesses receiving an investment from TEDCO’s Pre-Seed Builder Fund, housed under TEDCO’s Social Impact Funds, receive access to a variety of benefits designed to nurture business growth.

“The promise of biologic drugs has been hampered by the need for frequent injections and cold-chain logistics,” said Derese Getnet, CEO of Simmbion. “Through the assistance of TEDCO, Simmbion is working to eliminate the need for recurrent needle-based administration of these drugs (and all the associated cold-chain). In success, our approach will transform adherence to treatment for diabetes, obesity, rare genetic diseases and cancer.”

BALTIMORE–(BUSINESS WIRE)–Techstars, Johns Hopkins University, and CareFirst BlueCross BlueShield (CareFirst) announced today a collaboration to launch a new healthcare accelerator program designed to support early-stage entrepreneurs building pathways to better care through artificial intelligence.

The next cycle of the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program is just around the corner, with a critical submission deadline set for January 5th, 2025. This highly competitive program offers early-stage funding opportunities for small businesses engaged in research and development that addresses significant biomedical challenges.

The NIH SBIR program provides a powerful vehicle for small businesses to accelerate the commercialization of cutting-edge technologies in fields such as biotechnology, pharmaceuticals, medical devices, and healthcare IT. Through this program, businesses can secure non-dilutive funding to advance their innovative solutions while gaining access to NIH’s vast network of resources and expertise.

Now is the time for eligible companies to prepare their proposals. Securing funding through the NIH SBIR program requires a robust and well-articulated application that clearly demonstrates the proposed project’s scientific merit, innovation, and commercial potential. Companies should also ensure they meet all eligibility requirements and align their research with NIH’s priorities.

This September 19^th, the BioHealth Capital Region Investment Conference will once again serve as a premier gathering for the biopharma sector, uniting a dynamic blend of participants, including industry executives, investors, and exciting early-stage companies. Known for fostering impactful collaborations and driving innovation, the free-to-attend conference on the third day of BioHealth Capital Region Week is an essential event for those invested in the continued growth of the BioHealth Capital Region.

As part of this event, BioHealth Innovation (BHI) invites you to connect with our expert Analyst Team, led by Jon Nelson. This team plays a pivotal role in advancing the biohealth ecosystem by offering strategic insights within the non-dilutive funding space that help drive success for startups and established companies.

Attendees registered will have the unique opportunity to schedule one-on-one meetings with Jon Nelson. These sessions offer a chance to discuss non-dilutive funding, gain valuable guidance from a team deeply embedded in the grant landscape, and explore potential options for grant assistance. The BHI Analyst Team is equipped to provide the support you need to achieve your goals.